These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30572609)

  • 1. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors.
    Zhao LM; Guo Z; Xue YJ; Min JZ; Zhu WJ; Li XY; Piao HR; Jin CH
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30572609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
    Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
    Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel benzo[c][1,2,5]thiadiazol-5-yl and thieno[3,2-c]- pyridin-2-yl imidazole derivatives as ALK5 inhibitors.
    Guo Z; Song X; Zhao LM; Piao MG; Quan J; Piao HR; Jin CH
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2070-2075. PubMed ID: 31303386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
    Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
    Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
    Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity.
    Yang YX; Guo J; Liu C; Nan JX; Wu YL; Jin CH
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400131. PubMed ID: 38678538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Sreenu D; Krishnaiah M; Subrahmanyam VB; Rao KS; Nagendra Mohan AV; Park CY; Son JY; Son DH; Park HJ; Sheen YY; Kim DK
    Eur J Med Chem; 2011 Sep; 46(9):3917-25. PubMed ID: 21696866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
    Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
    Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
    Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Krishnaiah M; Jin CH; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Jung SH; Lee HS; Dewang PM
    Eur J Med Chem; 2009 Feb; 44(2):568-76. PubMed ID: 18467006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors.
    Xu G; Zhang Y; Wang H; Guo Z; Wang X; Li X; Chang S; Sun T; Yu Z; Xu T; Zhao L; Wang Y; Yu W
    Eur J Med Chem; 2020 Jul; 198():112354. PubMed ID: 32387837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
    Li X; Wang L; Long L; Xiao J; Hu Y; Li S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
    Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
    Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
    Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
    Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the TGF-β receptor with kinase inhibitors for scleroderma therapy.
    Cong L; Xia ZK; Yang RY
    Arch Pharm (Weinheim); 2014 Sep; 347(9):609-15. PubMed ID: 24917246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.